Annual report pursuant to Section 13 and 15(d)

Acquisition of Patents and Intangibles - Consideration and allocation (Details)

v3.21.2
Acquisition of Patents and Intangibles - Consideration and allocation (Details) - USD ($)
Nov. 16, 2018
Oct. 16, 2012
May 31, 2021
May 31, 2020
Asset Acquisition [Line Items]        
Acquired intangible assets     $ 1,653,000 $ 13,456,000
Leronlimab P R O 140 Acquisition [Member]        
Asset Acquisition [Line Items]        
Total consideration in asset purchase   $ 3,500,000    
Acquired intangible assets     $ 3,500,000 $ 3,500,000
Prosta Gene L L C Acquisition [Member]        
Asset Acquisition [Line Items]        
Equity issued $ 11,558,000      
Acquisition costs 741,000      
Release of deferred tax asset 2,827,000      
Total consideration in asset purchase 15,126,000      
Acquired intangible assets 15,126,000      
Other Assets 0      
Total acquired assets $ 15,126,000